Ligand Pharmaceuticals Inc. Collaborator Drug Shows Encouraging Results In Thrombocytopenia; GlaxoSmithKline Releases Phase II Data; Ligand Drug For Thrombocytopenia Targeted For IND Filing 1H'06
SAN DIEGO--(BUSINESS WIRE)--Dec. 2, 2005--Ligand Pharmaceuticals Incorporated (Pink Sheets:LGND) announced today that results reported by GlaxoSmithKline (NYSE:GSK) in phase II studies of eltrombopag, SB-497115 ("115"), a small-molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor that promotes growth and production of blood platelets, were promising.